Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Baxter International Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Baxter International Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Baxter International Inc. P/E ratio decreased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016. |
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Baxter International Inc. P/OP ratio decreased from Q4 2015 to Q1 2016 but then increased from Q1 2016 to Q2 2016 exceeding Q4 2015 level. |
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Baxter International Inc. P/S ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Baxter International Inc. P/BV ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016. |
Price to Earnings (P/E)
Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
Selected Financial Data (US$) | |||||||||||||||||||||||||||||
Net income attributable to Baxter (in millions) | |||||||||||||||||||||||||||||
Earnings per share (EPS)2 | |||||||||||||||||||||||||||||
Share price1, 3 | |||||||||||||||||||||||||||||
Valuation Ratio | |||||||||||||||||||||||||||||
P/E ratio4 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
P/E Ratio, Competitors5 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Group | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Humana Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2016 Calculation
EPS
= (Net income attributable to BaxterQ2 2016
+ Net income attributable to BaxterQ1 2016
+ Net income attributable to BaxterQ4 2015
+ Net income attributable to BaxterQ3 2015)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.
4 Q2 2016 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Baxter International Inc. P/E ratio decreased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016. |
Price to Operating Profit (P/OP)
Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
Selected Financial Data (US$) | |||||||||||||||||||||||||||||
Operating income (in millions) | |||||||||||||||||||||||||||||
Operating profit per share2 | |||||||||||||||||||||||||||||
Share price1, 3 | |||||||||||||||||||||||||||||
Valuation Ratio | |||||||||||||||||||||||||||||
P/OP ratio4 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
P/OP Ratio, Competitors5 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Group | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Humana Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2016 Calculation
Operating profit per share
= (Operating incomeQ2 2016
+ Operating incomeQ1 2016
+ Operating incomeQ4 2015
+ Operating incomeQ3 2015)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.
4 Q2 2016 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Baxter International Inc. P/OP ratio decreased from Q4 2015 to Q1 2016 but then increased from Q1 2016 to Q2 2016 exceeding Q4 2015 level. |
Price to Sales (P/S)
Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
Selected Financial Data (US$) | |||||||||||||||||||||||||||||
Net sales (in millions) | |||||||||||||||||||||||||||||
Sales per share2 | |||||||||||||||||||||||||||||
Share price1, 3 | |||||||||||||||||||||||||||||
Valuation Ratio | |||||||||||||||||||||||||||||
P/S ratio4 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
P/S Ratio, Competitors5 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Group | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Humana Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2016 Calculation
Sales per share
= (Net salesQ2 2016
+ Net salesQ1 2016
+ Net salesQ4 2015
+ Net salesQ3 2015)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.
4 Q2 2016 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Baxter International Inc. P/S ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016. |
Price to Book Value (P/BV)
Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
Selected Financial Data (US$) | |||||||||||||||||||||||||||||
Total Baxter shareholders’ equity (in millions) | |||||||||||||||||||||||||||||
Book value per share (BVPS)2 | |||||||||||||||||||||||||||||
Share price1, 3 | |||||||||||||||||||||||||||||
Valuation Ratio | |||||||||||||||||||||||||||||
P/BV ratio4 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
P/BV Ratio, Competitors5 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Group | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Humana Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2016 Calculation
BVPS = Total Baxter shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Baxter International Inc. Quarterly or Annual Report.
4 Q2 2016 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Baxter International Inc. P/BV ratio increased from Q4 2015 to Q1 2016 and from Q1 2016 to Q2 2016. |